Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: Demonstration in female-to-male transgender patients

Abstract

Context: Testosterone (T) is commonly administered intramuscularly to treat hypogonadal males and female-to-male (FTM) transgender patients. However, these injections can involve significant discomfort and may require arrangements for administration by others. Objective: Weassessed whether T could be administered effectively and safely subcutaneously as an alternative to intramuscular (IM) injections. Design: Retrospective cohort study. Setting: Outpatient reproductive endocrinology clinic at an academic medical center. Patients: Sixty-three FTM transgender patients aged.18 years electing to receive subcutaneous (SC) T therapy for sex transition were included. Fifty-three patients were premenopausal. Intervention: Patients were administered T cypionate or enanthate weekly at an initial dose of 50 mg. Dose was adjusted if needed to achieve serum total T levels within the normal male range. Main Outcome Measurements: Serum concentrations of free and total T and total estradiol (E2), masculinization, and surveillance for reactions at injection sites. Results: Serum T levels within the normal male range were achieved in all 63 patients with doses of 50 to 150mg(median, 75/80 mg). Therapy was effective across a wide range of body mass index (19.0 to 49.9 kg/m2). Minor and transient local reactions were reported in 9 out of 63 patients. Among 53 premenopausal patients, 51 achieved amenorrhea and 35 achieved serum E2 concentrations ,50 pg/mL. Twenty-two patients were originally receiving IM and switched to SC therapy. All 22 had a mild (n = 2) or marked (n = 20) preference for SC injections; none preferred IM injections. Conclusions: Our observations indicate that SC T injections are an effective, safe, and well-accepted alternative to IM T injections.